Abliva
0.443
SEK
+0.11 %
Less than 1K followers
ABLI
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
+0.11%
-1.56%
+4.98%
+214.63%
+140.5%
+186.18%
+4.02%
-36.56%
-90.12%
Abliva is a pharmaceutical company focused on developing innovative treatments for neurological diseases. The company is researching new therapies that can improve the quality of life for patients with neurological conditions. The company operates globally with a primary presence in Europe and North America. Abliva was founded in 2018 and is headquartered in Lund, Sweden.
Read moreMarket cap
714.06M SEK
Turnover
131.81K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Financial calendar
28.3
2025
Extraordinary general meeting '25
22.5
2025
Interim report Q1'25
12.6
2025
General meeting '25
ShowingAll content types
Notice of Extraordinary General Meeting in Abliva AB (publ)
Abliva applies for delisting and will convene an extraordinary general meeting
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools